



AMCP Advocates Visit Congress for Legislative Days 2023

Last month, 31 volunteer advocates made the trip to Washington DC for AMCP Legislative Days 2023. AMCP members from across the country came to the nation's capital to urge their leaders in Congress to support AMCP's legislative priorities. On May 23, AMCP awarded Representatives Brett Guthrie (R-KY) and Anna Eshoo (D-CA) the Achievement in Pharmacy Policy Award for their work securing passage of the Pre-approval Information Exchange Act last year. On May 24, AMCP advocates attended a total of 66 Congressional meetings, representing 23 states. They discussed AMCP's top legislative priorities in 2023 and urged their Representatives and Senators to support bills that would advance the practice of managed care pharmacy nationwide. These include the:

- [Access to Prescription Digital Therapeutics Act \(S.723/H.R.1458\)](#)
- [Medicaid VBPs for Patients Act \(H.R. 2666\)](#)
- [Equitable Community Access to Pharmacist Services Act \(H.R. 1770\)](#)
- [Pharmacy and Medically Underserved Areas Enhancement Act \(S. 1491\)](#)

Want to take action? Ask your Members of Congress to support these priorities with [AMCP's Take Action page](#).

APPROVED

**For Non-Muscle Invasive
Bladder Cancer (NMIBC)**

Learn More

Ferring and the Ferring Pharmaceuticals logo are registered trademarks of Ferring B.V.
© 2023 Ferring B.V. All rights reserved. US-ADST-2300030 05/23

FERRING
PHARMACEUTICALS

AMCP Submits Comments on Manufacturer Discount Program Draft Guidance

The Medicare Part D Manufacturer Discount Program, implemented as part of the Inflation Reduction Act (IRA), requires participating manufacturers to provide discounts on certain drugs in the initial and catastrophic coverage phases of the Part D benefit. On May 12, CMS released draft guidance for the implementation of this provision. Given the opportunity to provide feedback, AMCP submitted comments in response to the guidance on June 12. In the comment letter, AMCP welcomes CMS' intent to incorporate the framework from the existing Coverage Gap Discount Program into the new Manufacturer Discount Program. AMCP also urges CMS to remain vigilant for unintended consequences throughout the implementation of the Discount Program and encourages the agency to protect the flexibilities which allow stakeholders to innovate ideas for increasing medication access while reducing prices.

[Read AMCP's full comment letter.](#)

AMCP to Showcase Prescription Digital Therapeutics (PDTs) on Capitol Hill

PDTs are FDA-authorized, software-based therapies that deliver clinical benefits to patients. Yet, these treatments are not covered by the Medicare and Medicaid programs, leaving vulnerable patients without access. In support of the Access to Prescription Digital Therapeutics Act (S.723/H.R. 1458), which establishes Medicare and Medicaid coverage categories for PDTs, AMCP will gather several PDT manufacturers on Capitol Hill this week to demonstrate their products in front of Members of Congress and their staff. The event was established with support from the Digital Therapeutics Alliance, and it aims to demonstrate PDTs' ability to identify, treat, and manage chronic diseases such as substance use disorders, attention-deficit hyperactivity disorder (ADHD), diabetes, and more.

APPROVED

**For
Non-Muscle
Invasive
Bladder
Cancer
(NMIBC)**

Learn More

Ferring and the Ferring Pharmaceuticals logo are registered trademarks of Ferring B.V.
© 2023 Ferring B.V.
All rights reserved.
US-ADST-2300030 05/23

FERRING
PHARMACEUTICALS

[Learn more about Prescription Digital Therapeutics.](#)

AMCP Comments on Proposed Rules Regarding Privacy and Health Data

This month saw the closure of several open comment periods on proposed rules regarding privacy and health data. On June 16, AMCP commented in support of a proposed rule from HHS titled “HIPAA Privacy Rule to Support Reproductive Health Care Privacy.” Specifically, AMCP supports an established definition for “reproductive health” and applauds HHS’ proposal to prevent the disclosure of an individual’s reproductive health care information in a criminal investigation when such care was provided or sought lawfully. On June 20, AMCP also commented on a proposed rule from HHS’ Office of the National Coordinator for Health Information that would establish national standards to promote system interoperability, create a new baseline version of the United States Core Data for Interoperability, and set real-time prescription benefit health IT certification criterion. AMCP’s comments support these proposals while also offering suggestions to incorporate health equity.

[Read AMCP’s June 16 comment letter.](#)

[Read AMCP’s June 20 comment letter.](#)

AMCP, Health Care Organizations Thank the Biden Administration for Relaunching the Cancer Moonshot

Last year, President Joe Biden relaunched the Cancer Moonshot initiative with a new national goal: reducing the death rate from cancer by at least 50% over the next 25 years. In May of this year, AMCP joined dozens of other health care organizations in thanking the Administration for reigniting the initiative, prioritizing cancer prevention, and referencing the importance of human papillomavirus (HPV) vaccination in achieving the new goal. The

sign-on letter references several proposals to significantly reduce the incidence of cancer from HPV across the country and offers the collaboration of signing organizations in that effort.

[Read the full letter.](#)